Neoantigen: A New Breakthrough in Tumor Immunotherapy
- Identification of Neoantigens
- Influencing factors for the generation of neoantigens
- Application of neoantigen immunotherapy
- Progress in Neoantigen Targeted Cancer Immunotherapies
Event details
|
DATE Wednesday, Nov 30, 2022 VENUE Online Webex / Zoom TIME 9:00 – 10:00 Berlin time (CET) 16:00 – 17:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Nov 29, 2022 |
PRESENTERS Lingling Cao, CEO & Founder Dr Hank Wang, Medical advisor Guest speaker REGISTER +86 21 5386 3003 BD@lingmed.net |
Agenda
| CET 9:00 - 9:30 | Neoantigen: A New Breakthrough in Tumor Immunotherapy |
by Dr Hank Wang (Chinese) |
| CET 9:30 - 9:35 | Linkedbio services & projects introduction | by Lingling Cao (English) |
| CET 9:35 - 9:55 | An innovative biotech roadshow | by Guest speaker (English) |
| CET 9:55 – 10:00 | Q&A | (English & Chinese) |
Presenters
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 20 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |